Appendix 3: Suggested birth plan

Serology results

Local birth plans may also be used provided they are informed by these guidelines.

GENITAL HERPES BIRTH PLAN

Copies to Genitourinary medicine (GUM), Midwife, Obstetrics, Neonatology, and GP (with patient permission)

MOTHER'S / BIRTHII	NG PARENT'S DETAILS	
Name		DOB//
Address		
Mobile		
Hospital number		GUM number
Consent given to rec	ord GUM number in hos	pital records
Estimated date of de	elivery / /	_
MOTHER'S / BIRTHII	NG PARENT'S HERPES D	IAGNOSIS
Diagnosis (based on	PCR)	
Genital HSV-1 □	Genital HSV-2 \square	Presumed genital HSV (type unknown) \square
Oro-labial cold sores	(HSV-1), (PCR confirmat	ion not required) 🗆

HSV-1 IgG positive \square	HSV-2 IgG positive \square	serology awaited \square	serology not done \square	
Date of acquisition				
Prior to pregnancy \Box	1^{st} trimester \square	2^{nd} trimester $\ \square$	3 rd trimester \square	
If acquired in pregnanc	y: date of first lesions: _	/ / at ge	station/40	
MOTHER'S / BIRTHING	PARENT'S HERPES MAI	NAGEMENT		
Antiviral suppression i	n pregnancy			
Standard:				
Aciclovir 400mg 3 time	s a day orally from 32 wo	eeks 🗆		
Valaciclovir 500mg 2 ti	mes a day orally from 32	weeks 🗆		
High risk of preterm de	livery:			
Acicovir 400mg 2 times	a day orally from 22 we	eks, then 3 times a day	orally from 32 weeks	
Valacicovir 500mg once	e a day orally from 22 we	eeks, then 2 times a day	orally from 32 weeks	
Preterm prelabour rupture of membranes:				
Aciclovir 5mg/kg IV eve	ery 8 hours 🗆			
Aciclovir 400mg 3 time	s a day orally from 32 we	eeks 🗆		
Valaciclovir 500mg 2 ti	Valaciclovir 500mg 2 times a day orally from 32 weeks □			

None: No antiviral suppression	has been taken □					
Other:						
Planned delivery method						
Vaginal delivery \square	Planned Caesarean	section on	_/ □			
POST DELIVERY URGENT MAN	AGEMENT					
Infants risk: highest \square	high \square	low 🗆	lowest □			
See management for baby for a	assessing risk, immed	liate investigatio	ns and management at end	of document in the neor	natal management section	1
Post natal advice has been give that their baby has potentially	·	0 0	edical review if their baby is	unwell up to 6 weeks p	ost birth and informing the	e clinician

Contact details for clinical teams

Specialty	Name	Email	Telephone
Genitourinary			
medicine consultant			
On call genitourinary			
medicine			
Obstetrics consultant			
On call obstetrics			
Midwife			
Delivery suite			
Neonatal consultant			
On call neonatology			

Paediatrics infectious		
diseases consultant		
(may be regional)		
On call paediatric		
infectious diseases		
(may be regional)		

NEONATAL MANAGEMENT

Immediate investigations and management

- All cases of possible neonatal HSV should be discussed urgently with the regional Paediatric Infectious Diseases Team [IV, C].
- Any positive HSV test from an infant must be managed as highest risk [IV, C].

Risk	Highest	High	Low	Lowest
Risk Delivery method	All infants with symptoms consistent with HSV infection regardless of delivery method Babies with any positive HSV	High Pregnant parent had an initial HSV infection within the previous 6 weeks and baby is asymptomatic and born by: • Vaginal delivery	Asymptomatic babies born by any delivery method in the presence of active recurrent herpes lesions Asymptomatic babies born at <37 weeks by any delivery method with	Asymptomatic babies born at >37 weeks by any delivery method with (99) with no active lesions in birthing woman or person at delivery AND a history of HSV infection more than 6 weeks previously
	test even if this is suspected to be detection of maternal HSV Babies born by vaginal delivery in the presence of active initial herpes lesions Birthing mother or parent	 Caesarean section regardless of duration of rupture of membranes 	no active lesions at delivery and a history of HSV infection more than 6 weeks previously	previously

	systemically unwell with			
	possible HSV			
	possible flot			
	Birthing mother or parent			
	presents post-partum with			
	active primary herpes lesions			
	within 4 weeks of delivery			
Clinical	Urgently inform the neonatal	Urgently inform the neonatal	Urgently inform the neonatal team	Inform the neonatal team
assessment	team	team		
				No investigations required
	Urgent assessment soon		Urgent assessment soon after birth	
	after birth, bearing in mind	Urgent assessment soon after	bearing in mind that the	Normal postnatal with a neonatal
	that the presentation of	birth bearing in mind that the	presentation of neonatal HSV may	examination at 24 hours of age, after
	neonatal HSV may be non-	presentation of neonatal HSV	be non-specific and that skin lesions	which the baby can be discharged from
	specific and that skin lesions	may be non-specific and that	may not be present. If evidence of	the hospital if well and feeding is
	may not be present	skin lesions may not be present.	neonatal HSV is found, investigate as	established
		If evidence of neonatal HSV is	per symptomatic infants.	
	Isolate infant from other	found, investigate as per		
	babies and nurse using	symptomatic infants.		
	barrier methods to reduce			
	the risk of postnatal	Isolate infant from other babies		
	transmission to other babies.	and nurse using barrier		
	Isolation should continue	methods to reduce the risk of		
	until neonatal herpes has	postnatal transmission to other		
	been excluded or treatment	babies. Isolation should		
	completed in the event of	continue until neonatal herpes		
	neonatal HSV being	has been excluded or treatment		
	confirmed.	completed in the event of		
		neonatal HSV being confirmed.		
	Ophthalmology review.			
Timing of	Urgent (note maternal or	24 hours post-delivery (note	24 hours post-delivery (note	
investigations	birth parent HSV may still be	maternal or birth parent HSV	maternal or birth parent HSV may	
	detected on surface swabs,	may still be detected on surface	still be detected on surface swabs	

	and therefore should be repeated if taken <24 hours of life)	swabs, and therefore should be repeated if taken <24 hours of life)	taken <24 hours of life)	
HSV PCR swab	Any visible lesions Throat swab Nose swab Conjunctival swabs Rectal swab	Throat swab Nose swab Conjunctival swabs Rectal swab	Throat swab Nose swab Conjunctival swabs Rectal swab	
Bloods	HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106) Full blood count Liver function tests Coagulation screen	HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106) Full blood count Liver function tests Coagulation screen	HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106)	
Lumbar puncture for CSF	If clinically safe, undertake lumbar puncture for CSF and send for:	If clinically safe, undertake lumbar puncture for CSF and send for:		
Other tests	As guided by the infant's clinical condition (for example chest X-ray)			

consider sending samples for drug resistance testing (available at the UK HAS laboratory at Collingdale) Management Urgently start aciclowir 20mg/kg 120mg/kg IV without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofrovir may be considered. Duration of treatment: All results are negative, and no other cause identified: 10 days Skin, eye and mouth disease only: 14 days CNS or disseminated disease, or no CNS obtainable but other positive HSV tests: 21 days. Send blood and CSF (if previously positive) on day 17-20 (near		In cases where drug resistance is a concern, discuss with a virologist and		
Urgently start aciclovir 20mg/kg Without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofovir may be considered. Duration of treatment:		drug resistance testing (available at the UK HAS		
depending on A long line may be considered	Management	Urgently start aciclovir 20mg/kg IV without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofovir may be considered. Duration of treatment:	IV without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofovir may be considered. Duration of treatment: • All results are negative, and baby remains asymptomatic: 10 days • Positive skin swab from completely intact skin: 10 days. • Positive skin swabs from areas of trauma without vesicles should be treated as per highest risk. • If baby becomes symptomatic or if any test is positive manage as per highest risk	

	duration of	to avoid extravasation of IV		
	laboratory result	aciclovir.		
	return times) for			
	HSV PCR to ensure			
	negative prior to			
	stopping treatment			
	on day 21. If CSF			
	remains positive,			
	continue IV aciclovir			
	for a further week			
	and repeat blood			
	and CSF prior to			
	stopping IV aciclovir.			
	IF a further positive			
	test is obtained,			
	provide a further			
	week of IV aciclovir.			
A long	line may be			
_	ered to avoid			
extrava	asation of IV aciclovir.			
Oral ac	ciclovir prophylaxis at			
	m ³ TDS for 6 months			
	t post IV therapy for			
	nts with CNS or			
dissem	inated disease and			
	ered in infants with			
	ye and mouth disease			
to redu	uce risk of CNS			
recurre	ences.			
Advice to Practic	e good hand hygiene ar	l nd take care to reduce risk of postna	latal infection from maternal genital secr	etions or other sources including anyone

parents and	with oral HSV-1.		
carers	Seek urgent medical help if they have concerns regarding their baby in the next 6 weeks, in particular:		
	Skin, eye and mucous membrane lesions		
	Lethargy/irritability		
	Poor feeding		
	• Fever		